Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wall

Showing results (431-440 of 448) with videos related to

Pageof 45
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
The Lancet. Infectious Diseases|June 8, 2023
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infectionEdward J Carr, Mary Y Wu, Joshua Gahir, et al.
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Discovery and Characterization of a Pan-betacoronavirus S2-binding antibodyNicole V Johnson, Steven C Wall, Kevin J Kramer, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
Structure (London, England : 1993)|September 26, 2024
Discovery and characterization of a pan-betacoronavirus S2-binding antibodyNicole V Johnson, Steven C Wall, Kevin J Kramer, et al.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
The Neurologist|January 20, 2026
Cervical Artery Dissection Diagnosed Following Chiropractic Cervical Manipulation: A STOP-CAD SubanalysisRozaleen Aleyadeh, Marialuisa Zedde, Joao P Marto, et al.
Lancet (London, England)|June 22, 2023
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest LondonChris Bailey, Theo Sanderson, Hermaleigh Townsley, et al.
Lancet (London, England)|January 29, 2022
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 45

Showing results (431-440 of 448) with videos related to

Sort By:
Pageof 45
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
The Lancet. Infectious Diseases|June 8, 2023
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infectionEdward J Carr, Mary Y Wu, Joshua Gahir, et al.
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Discovery and Characterization of a Pan-betacoronavirus S2-binding antibodyNicole V Johnson, Steven C Wall, Kevin J Kramer, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
Structure (London, England : 1993)|September 26, 2024
Discovery and characterization of a pan-betacoronavirus S2-binding antibodyNicole V Johnson, Steven C Wall, Kevin J Kramer, et al.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
The Neurologist|January 20, 2026
Cervical Artery Dissection Diagnosed Following Chiropractic Cervical Manipulation: A STOP-CAD SubanalysisRozaleen Aleyadeh, Marialuisa Zedde, Joao P Marto, et al.
Lancet (London, England)|June 22, 2023
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest LondonChris Bailey, Theo Sanderson, Hermaleigh Townsley, et al.
Lancet (London, England)|January 29, 2022
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 45